Full Press Release Details
dupixent dupilumab significantly reduced copd exacerbations in second positive phase 3 trial accelerating fda submission and confirming potential to become first approved biologic.
REGN
dupixent dupilumab significantly reduced copd exacerbations in second positive phase 3 trial accelerating fda submission and confirming potential to become first approved biologic
Key Takeaway: dupixent dupilumab significantly reduced copd exacerbations in second positive phase 3 trial accelerating fda submission and confirming potential to become first approved biologic